Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structure of the Bcr-Abl oncoprotein oligomerization domain.

Nature structural biology - 1 Feb 2002

Zhao Xun, Ghaffari Saghi, Lodish Harvey, Malashkevich Vladimir N, Kim Peter S

Abstract excerpt

The Bcr-Abl oncoprotein is responsible for a wide range of human leukemias, including most cases of Philadelphia chromosome-positive chronic myelogenous leukemia. Oligomerization of Bcr-Abl is essential for oncogenicity. We determined the crystal structure of the N-terminal oligomerization domain of Bcr-Abl (residues 1-72 or Bcr1-72) and found a novel mode of oligomer formation. Two N-shaped monomers dimerize by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Crystallization
Share to Crystallography, X-Ray
Share to Dimerization

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Design

Share to Enzyme Activation

Share to Enzyme Inhibitors

Share to Fusion Proteins, bcr-abl

Share to Protein Structure, Quaternary

Source

Identifiers

PMID: 11780146
DOI: 10.1038/nsb747

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structure of the Bcr-Abl oncoprotein oligomerization domain.PMID 11780146Read ↗

A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.Semantic proximity Read ↗

Structure and dynamic regulation of Abl kinases.Semantic proximity Read ↗

The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemiaSemantic proximity Read ↗

Structure, Regulation, Signaling, and Targeting of Abl Kinases in CancerSemantic proximity Read ↗

Autoinhibition of Bcr-Abl through its SH3 domain.Semantic proximity Read ↗

Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase InterfaceSemantic proximity Read ↗

The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug.Semantic proximity Read ↗

Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL.Semantic proximity Read ↗

Charting the molecular network of the drug target Bcr-AblSemantic proximity Read ↗

The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL.Semantic proximity Read ↗

Autophosphorylation of the oncogenic protein TEL-ABL confers resistance to the allosteric ABL inhibitor asciminibSemantic proximity Read ↗

c-Abl Tyrosine Kinase Adopts Multiple Active Conformational States in Solution.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.